Literature DB >> 17225881

Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation.

Kathy Han1, George N Tzimas, Jeffrey S Barkun, Peter Metrakos, Jean L Tchervenkov, Nir Hilzenrat, Phil Wong, Marc Deschênes.   

Abstract

BACKGROUND: Liver transplantation (LT) offers a possible cure for patients with hepatocellular carcinoma (HCC) and cirrhosis. However, tumour progression while on the waiting list and tumour recurrence after LT are common. The prognostic significance of various pre- and postoperative variables were investigated in regard to tumour recurrence, with an emphasis on the slope of preoperative serum alpha-fetoprotein (AFP) levels. patients and
METHODS: Data from 48 patients who had HCC diagnosed preoperatively and underwent LT at the McGill University Health Centre (Montreal, Quebec) were reviewed retrospectively, and possible risk factors for tumour recurrence were examined.
RESULTS: Univariate analysis revealed a positive correlation between the preoperative AFP slope and vascular invasion (P = 0.045), total tumour diameter at explant (P = 0.040), Cancer of the Liver Italian Program score (P = 0.017) and recurrence-free survival (P = 0.028). Of the preoperative variables examined, only the preoperative AFP slope was identified as an independent predictor of tumour recurrence by multivariate analysis. Receiver operating characteristic analysis showed that the best discriminant cut-off value, calculated as the value of the maximized likelihood ratio, was preoperative AFP slope greater than 50 microg/L per month. At this cut-off, sensitivity was 36%, and specificity was 97%. Patients with a preoperative AFP slope greater than 50 microg/L per month had a much worse one-year recurrence-free survival rate than those with a preoperative AFP slope 50 microg/L per month or less (40% versus 90%, P < 0.001).
CONCLUSIONS: These results suggest that the preoperative AFP slope is an important predictor of HCC recurrence after LT and should be examined in future studies of patients receiving LT for HCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17225881      PMCID: PMC2656629          DOI: 10.1155/2007/206383

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  28 in total

1.  Clinicopathological features of incidental hepatocellular carcinoma in liver transplantation.

Authors:  S H Choi; H H Lee; D S Lee; J H Choi; J S Heo; K W Lee; J W Joh; S J Kim; B C Yoo; J H Lee; M S Choi; Y H Choe; S K Lee
Journal:  Transplant Proc       Date:  2004-10       Impact factor: 1.066

Review 2.  Selection of patients with hepatocellular carcinoma for liver transplantation.

Authors:  R Sutcliffe; D Maguire; B Portmann; M Rela; N Heaton
Journal:  Br J Surg       Date:  2006-01       Impact factor: 6.939

3.  Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation.

Authors:  H J Schlitt; M Neipp; A Weimann; K J Oldhafer; E Schmoll; K Boeker; B Nashan; S Kubicka; H Maschek; G Tusch; R Raab; B Ringe; M P Manns; R Pichlmayr
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

4.  Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic?

Authors:  Georgios C Sotiropoulos; Massimo Malagó; Ernesto Molmenti; Andreas Paul; Silvio Nadalin; Eirini Brokalaki; Hilmar Kühl; Olaf Dirsch; Hauke Lang; Christoph E Broelsch
Journal:  Transplantation       Date:  2005-02-27       Impact factor: 4.939

5.  Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?

Authors:  J W Marsh; I Dvorchik; C A Bonham; S Iwatsuki
Journal:  Cancer       Date:  2000-02-01       Impact factor: 6.860

6.  A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.

Authors: 
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

7.  Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels.

Authors:  P Tangkijvanich; N Anukulkarnkusol; P Suwangool; S Lertmaharit; O Hanvivatvong; P Kullavanijaya; Y Poovorawan
Journal:  J Clin Gastroenterol       Date:  2000-12       Impact factor: 3.062

Review 8.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

9.  Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power.

Authors:  J M Llovet; J Bruix; J Fuster; A Castells; J C Garcia-Valdecasas; L Grande; A Franca; C Brú; M Navasa; M C Ayuso; M Solé; M I Real; R Vilana; A Rimola; J Visa; J Rodés
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079

View more
  23 in total

1.  Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation.

Authors:  Zhong-Bo Han; Hong-Yuan Chen; Jun-Wei Fan; Jun-Yi Wu; Hua-Mei Tang; Zhi-Hai Peng
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-10       Impact factor: 4.553

2.  Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study.

Authors:  Steven-Huy Han; K Rajender Reddy; Emmet B Keeffe; Consuelo Soldevila-Pico; Robert Gish; Raymond T Chung; Bulent Degertekin; Anna Lok
Journal:  Clin Transplant       Date:  2010-11-16       Impact factor: 2.863

3.  Predictors of liver transplant eligibility for patients with hepatocellular carcinoma in a safety net hospital.

Authors:  Amit G Singal; Vincent Chan; Yonas Getachew; Richard Guerrero; Joan S Reisch; Jennifer A Cuthbert
Journal:  Dig Dis Sci       Date:  2011-09-28       Impact factor: 3.199

4.  Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma.

Authors:  Fabrice Muscari; Jean-Pascal Guinard; Nassim Kamar; Jean-Marie Peron; Philippe Otal; Bertrand Suc
Journal:  World J Surg       Date:  2012-08       Impact factor: 3.352

5.  Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation.

Authors:  Zhong-Bo Han; Lin Zhong; Mu-Jian Teng; Jun-Wei Fan; Hua-Mei Tang; Jun-Yi Wu; Hong-Yuan Chen; Zhao-Wen Wang; Guo-Qiang Qiu; Zhi-Hai Peng
Journal:  Mol Oncol       Date:  2012-04-17       Impact factor: 6.603

6.  Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.

Authors:  Michał Grąt; Oskar Kornasiewicz; Zbigniew Lewandowski; Wacław Hołówko; Karolina Grąt; Konrad Kobryń; Waldemar Patkowski; Krzysztof Zieniewicz; Marek Krawczyk
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

7.  Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA.

Authors:  Mohamed Abd El-Fattah
Journal:  Indian J Gastroenterol       Date:  2017-02-14

Review 8.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 9.  Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes.

Authors:  Chih-Che Lin; Chao-Long Chen
Journal:  Hepatobiliary Surg Nutr       Date:  2016-10       Impact factor: 7.293

10.  Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.

Authors:  Khairuddin Memon; Laura Kulik; Robert J Lewandowski; Edward Wang; Robert K Ryu; Ahsun Riaz; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Talia Baker; Michael Abecassis; Al B Benson; Mary F Mulcahy; Reed A Omary; Riad Salem
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.